How much funding can be received?

There is no informations about how much funding can be received.

What is the deadline to apply?

The deadline to apply is not specified.

Who are the financial supporters of the NRC — Cell Culture Pilot Plant?

NRC — Cell Culture Pilot Plant is funded by National Research Council Canada (NRC), Government of Canada

What are NRC — Cell Culture Pilot Plant's eligibility criterias?

The applicant must be involved in biotechnology, focusing on the production and purification of biologics or vaccines. The project should require access to advanced bioprocessing services and equipment for cell culture scale-up. The applicant must seek to optimize or mimic existing cGMP-compatible bioprocesses for potential transition to a contract manufacturing organization.

NRC — Cell Culture Pilot Plant

Montréal, QC

Biologics and vaccine production facility in Montreal

grant_single|update January 24, 2025

grant_single_labels|summary

grant_single_labels|preview

grant_single_labels|projects

grant_single_labels|admissibility

grant_single_labels|criteria

grant_single_labels|apply

grant_single_labels|otherInfo

grant_single_labels|documents

grant_single_labels|summary

grant_single|eligibleFinancing

grant_single|noCondition

grant_single|deadlines

grant_single|openingDateNovember 14, 2019

grant_single|financingType

Researchers And Facilities

grant_single|eligibleIndustries

Manufacturing
Professional, scientific and technical services
Health care and social assistance

grant_single|grantors

National Research Council Canada (NRC)
Government of Canada

grant_single|status

grant_card_status|open

grant_single_labels|preview

Fee-for-service cell culture pilot plant offering development and scale-up for the production of biologics and vaccines using CHO, HEK 293 and other animal cell expression systems.

grant_single_labels|projects

This grant facilitates the development and optimization of bioprocesses for biologics and vaccines, focusing on leveraging advanced cell culture systems. Eligible projects aim to enhance scale-up, purification, and production capabilities.

Development and scale-up of batch, fed-batch, or perfusion cell culture processes up to 500 L scale for biologics production.
Scale-up of viral production and purification processes.
Scale-up of transient transfection processes.
Development of cell culture media and feeding strategies for process optimization.
In-process assay development to ensure robust production outcomes.
Customized, hands-on training on bioreactor operation up to 500 L scale for technology transfer and workforce development.

grant_single|admissibleProjectsExample

$ 220,000

Development of custom cell culture media for the optimization of an antibody production process

$ 200,000

Conducting hands-on training for bioreactor operation up to 500 L scale

$ 250,000

Developing a 500 L scale bioreactor process for vaccine production using CHO cells

$ 270,000

Development and scale-up of a perfusion cell culture process for biologics production

$ 280,000

Optimization of transient transfection processes for the production of therapeutic proteins

$ 300,000

Scale-up of viral production processes for gene therapy applications

grant_single_labels|admissibility

Eligibility criteria:

Canadian biotechnology companies
Businesses involved in pilot-scale production and purification of biologics, viral vectors, and vaccines

grant_eligibility_criteria|who_can_apply

This program is ideal for biotechnology companies involved in the pilot-scale production and purification of recombinant proteins, viral vectors, and vaccines. It is particularly suited for those aiming to optimize cGMP-compatible bioprocesses and work towards a robust Canadian biomanufacturing sector. The program supports the scale-up process using advanced bioprocessing services and equipment.

grant_eligibility_criteria|eligible_expenses

The grant supports projects focused on advancing bioprocessing services and equipment for the production of biologics and vaccines. It emphasizes process development and scale-up for various cell culture systems and optimization strategies.

Development and scale-up of batch, fed-batch, or perfusion cell culture processes up to 500 L scale for biologics production.
Scale-up of viral production and purification processes.
Scale-up of transient transfection processes.
Development of cell culture media and feeding strategies for process optimization.
In-process assay development.
Customized, hands-on training on bioreactor operation up to 500 L scale.

grant_eligibility_criteria|zone

This grant is aimed at fostering the Canadian biomanufacturing sector, suggesting a focus on companies within Canada. The explicit geographical eligibility details are not provided in the available text.

grant_single_labels|criteria

Grant applications will be assessed based on key criteria including scientific excellence, feasibility, impact, and alignment with the objectives of the Human Health Therapeutics Research Centre.

Scientific excellence
Feasibility of the proposed project
Potential impact of the project
Alignment with the objectives of the Human Health Therapeutics Research Centre

grant_single_labels|apply

grant_single_labels|otherInfo

Here are additional relevant details for this grant:

The NRC’s Human Health Therapeutics Research Centre offers specific expertise in developing high-performance liquid chromatography (HPLC) and cell-based assays.
The facility enables the transition from bench-scale process optimization to up to 500 L scale production.
The team provides customized, hands-on training on bioreactor operation up to a 500 L scale.
The cell culture pilot plant functions as an ideal facility for emerging technologies and facilitates transfer of optimized bioprocesses to a CMO.
The NRC owns proprietary versions of the HEK293 cell line, namely HEK293SF-3F6 and HEK293-6E.